Graves Ophthalmopathy

• EMA approval · 2026-03-25
  EMA Authorised: Tepezza (teprotumumab) — Amgen Europe B.V.

  The European Medicines Agency authorised Tepezza (teprotumumab) for Graves' ophthalmopathy, with Amgen Europe B.V. as the marketing authoriz…

• FDA approval · 2021-10-26
  FDA Approved: TEPEZZA — Supplemental Application (Horizon Therapeutics USA, Inc.)

  FDA approved a supplemental application for TEPEZZA (teprotumumab) by Horizon Therapeutics USA, Inc.

• FDA approval · 2020-01-21
  FDA Approved: TEPEZZA — Original Application (Horizon Therapeutics USA, Inc.)

  The FDA approved TEPEZZA (teprotumumab) from Horizon Therapeutics USA, Inc. under an original biologics license application. This marks the …